Table 1.
Clinical, laboratory, and pathological characteristics of study population.
| Variables | HBeAg-positive (n = 254) | HBeAg-negative (n = 237) | χ 2a /Z b | P # |
|---|---|---|---|---|
| Gender (male : female) | 163 : 91 | 145 : 92 | 0.350a | 0.5540 |
| Age (years), median (IQR) | 33 (28–39) | 42 (35–49) | 9.475b | <0.0001 |
| Serum ALT (IU/L), median (IQR) | 67.5 (40.0–154.0) | 35.0 (20.0–93.5) | 6.587b | <0.0001 |
| Serum AST (IU/L), median (IQR) | 46.0 (29.0–89.0) | 28.0 (19.0–56.3) | 6.161b | <0.0001 |
| Serum GGT (IU/L), median (IQR) | 31.0 (18.0–71.0) | 26.0 (16.8–55.3) | 1.751b | 0.0799 |
| Serum ChE (kU/L), median (IQR) | 7.525 (6.493–9.086) | 8.378 (6.785–9.669) | 3.177b | 0.0015 |
| Blood PLT (×109/L), median (IQR) | 171 (139–207) | 169 (127–208) | 1.017b | 0.3091 |
| Serum anti-HBc (log10 IU/L), median (IQR) | 3.526 (3.137–3.806) | 4.222 (3.668–4.641) | 10.747b | <0.0001 |
| Serum HBsAg (log10 IU/L), median (IQR) | 4.010 (3.446–4.596) | 3.282 (2.762–3.615) | 11.902b | <0.0001 |
| Serum HBV DNA (log10 IU/L), median (IQR) | 7.228 (6.336–7.806) | 3.565 (<2.699–5.235) | 15.327b | <0.0001 |
| Intrahepatic HBsAg (0 : 1 : 2 : 3) | 3 : 54 : 95 : 102 | 17 : 104 : 82 : 34 | 60.061a | <0.0001 |
| Intrahepatic HBcAg (0 : 1 : 2 : 3) | 103 : 70 : 64 : 17 | 207 : 27 : 3 : 0 | 126.052a | <0.0001 |
| Pathological grade (0 : 1 : 2 : 3 : 4) | 0 : 153 : 85 : 16 : 0 | 0 : 182 : 39 : 16 : 0 | 19.009a | 0.0001 |
| Pathological stage (0 : 1 : 2 : 3 : 4) | 0 : 115 : 89 : 16 : 34 | 0 : 140 : 47 : 16 : 34 | 14.851a | 0.0019 |
IQR, interquartile range; ALT, alanine transferase; AST, aspartate transferase; GGT, gamma-glutamyl transpeptidase; ChE, cholinesterase; PLT, platelet; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBcAg, hepatitis B core antigen; anti-HBc, antibodies to hepatitis B core antigen; HBV DNA, hepatitis B virus DNA. #Comparison between HBeAg-positive and HBeAg-negative patients; aPearson chi-square test; bMann–Whitney U test.